Novartis is buying a U.K. cancer drug startup for up to $1.5 billion
Culture Index
Score Breakdown
Relevance
9/25
Freshness
25/25
Authority
18/20
Brand Signal
2/15
Depth
2/15
5-Axis Cultural Radar
The Swiss drugmaker will pay $1.1 billion upfront and up to $400 million in milestones to gain a novel antibody-drug conjugate payload platform
